Literature DB >> 12057663

10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.

Thomas H Marsilje1, Marc A Labroli, Michael P Hedrick, Qing Jin, Joel Desharnais, Stephen J Baker, Lata T Gooljarsingh, Joseph Ramcharan, Ali Tavassoli, Yan Zhang, Ian A Wilson, G Peter Beardsley, Stephen J Benkovic, Dale L Boger.   

Abstract

The synthesis of 10-formyl-DDACTHF (3) as a potential inhibitor of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) is reported. Aldehyde 3, the corresponding gamma- and alpha-pentaglutamates 21 and 25 and related agents were evaluated for inhibition of folate-dependent enzymes including GAR Tfase and AICAR Tfase. The inhibitors were found to exhibit potent cytotoxic activity (CCRF-CEM IC(50) for 3=60nM) that exceeded their enzyme inhibition potency [K(i) (3)=6 and 1 microM for Escherichia coli GAR and human AICAR Tfase, respectively]. Cytotoxicity rescue by medium purines, but not pyrimidines, indicated that the potent cytotoxic activity is derived from selective purine biosynthesis inhibition and rescue by AICAR monophosphate established that the activity is derived preferentially from GAR versus AICAR Tfase inhibition. The potent cytotoxic compounds including aldehyde 3 lost activity against CCRF-CEM cell lines deficient in the reduced folate carrier (CCRF-CEM/MTX) or folylpolyglutamate synthase (CCRF-CEM/FPGS(-)) establishing that their potent activity requires both reduced folate carrier transport and polyglutamation. Unexpectedly, the pentaglutamates displayed surprisingly similar K(i)'s versus E. coli GAR Tfase and only modestly enhanced K(i)'s versus human AICAR Tfase. On the surface this initially suggested that the potent cytotoxic activity of 3 and related compounds might be due simply to preferential intracellular accumulation of the inhibitors derived from effective transport and polyglutamation (i.e., ca. 100-fold higher intracellular concentrations). However, a subsequent examination of the inhibitors against recombinant human GAR Tfase revealed they and the corresponding gamma-pentaglutamates were unexpectedly much more potent against the human versus E. coli enzyme (K(i) for 3, 14nM against rhGAR Tfase versus 6 microM against E. coli GAR Tfase) which also accounts for their exceptional cytotoxic potency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057663     DOI: 10.1016/s0968-0896(02)00102-5

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.

Authors:  Jessica K DeMartino; Inkyu Hwang; Lan Xu; Ian A Wilson; Dale L Boger
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

2.  Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.

Authors:  Wanda Manieri; Molly E Moore; Matthew B Soellner; Pearl Tsang; Carol A Caperelli
Journal:  Biochemistry       Date:  2007-01-09       Impact factor: 3.162

3.  Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.

Authors:  Stephen Connelly; Jessica K DeMartino; Dale L Boger; Ian A Wilson
Journal:  Biochemistry       Date:  2013-07-19       Impact factor: 3.162

4.  Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.

Authors:  Jessica K DeMartino; Inkyu Hwang; Stephen Connelly; Ian A Wilson; Dale L Boger
Journal:  J Med Chem       Date:  2008-08-08       Impact factor: 7.446

5.  Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization.

Authors:  Ian B Spurr; Charles N Birts; Francesco Cuda; Stephen J Benkovic; Jeremy P Blaydes; Ali Tavassoli
Journal:  Chembiochem       Date:  2012-07-04       Impact factor: 3.164

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.